C5 and COVID-19: In support of the mechanism, targeted inhibition of C5a with vilobelimab has shown survival benefit in a randomized trial of critically-ill COVID-19 patients when administered within 48 hours of mechanical ventilation (101), underscoring the role of complement in disease pathogenesis.